Shoutout to first author, Isabella Alves, a @damonrunyon.org SPARK postbaccalaureate fellow and rising star in hematology. Very proud to see this work in print and honored to have had the opportunity to review the original article and learn more about the coolness of ferroptosis🩸🔮

The Clinical Investigator Award program was designed to increase the number of physician-scientists capable of translating discoveries in the lab into new treatments for cancer patients.

@tanaya-shree.bsky.social was recognized as one of five new @damonrunyon.org Clinical Investigators in 2025.

Learn more about these projects and our new Clinical Investigators:

@tanaya-shree.bsky.social‬ is researching the most effective design for a new type of immunotherapy, known as T-cell engaging bispecific antibodies, which bring T cells close to tumor cells and induce them to kill the tumor cell.

Srivatsan Raghavan, MD, PhD, aims to uncover how pancreatic cancer cells become resistant to KRAS inhibitors (which target the KRAS gene) and develop combination therapies to overcome this resistance.

Peter G. Miller, MD, PhD, studies how mutations in blood cells give rise to pre-malignant blood conditions such as clonal hematopoiesis, which can develop into leukemia. He hopes to develop strategies to predict and prevent lethal blood cancers.

@bkeenanmdphd.bsky.social is investigating how liver disease suppresses immune function and interferes with liver cancer treatment. She hopes to find combination therapies that can enhance the effectiveness of immunotherapy for these patients.

Jonathan Chou, MD, PhD, seeks to identify targetable proteins on the surface of bladder cancer cells, with the goal of engineering new cellular therapies for bladder cancer patients.